{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:59:52Z","timestamp":1791262792424,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2002,12,1]]},"DOI":"10.1038\/sj.bmt.1703733","type":"journal-article","created":{"date-parts":[[2002,12,13]],"date-time":"2002-12-13T11:57:22Z","timestamp":1039780642000},"page":"797-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?"],"prefix":"10.1038","volume":"30","author":[{"given":"G","family":"Hale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JM","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mackinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,12,12]]},"reference":[{"key":"BF1703733_CR1","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","volume":"304","author":"PL Weiden","year":"1981","unstructured":"Weiden PL, Sullivan KM, Fluornoy N et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation New Engl J Med 1981 304: 1529 1533","journal-title":"New Engl J Med"},{"key":"BF1703733_CR2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 1990 75: 555 562","journal-title":"Blood"},{"key":"BF1703733_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0140-6736(84)92564-9","volume":"2","author":"H Waldmann","year":"1984","unstructured":"Waldmann H, Polliak A, Hale G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1) Lancet 1984 2: 483 486","journal-title":"Lancet"},{"key":"BF1703733_CR4","first-page":"465","volume":"17","author":"S Slavin","year":"1985","unstructured":"Slavin S, Waldmann H, Or R et al. Prevention of graft-vs-host disease in allogeneic transplantation for leukemia by T-cell depletion in vitro prior to transplantation Transplant Proc 1985 17: 465 467","journal-title":"Transplant Proc"},{"key":"BF1703733_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/323164a0","volume":"323","author":"SP Cobbold","year":"1986","unstructured":"Cobbold SP, Martin G, Qin S, Waldmann H . Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance Nature 1986 323: 164 166","journal-title":"Nature"},{"key":"BF1703733_CR6","first-page":"597","volume":"13","author":"G Hale","year":"1994","unstructured":"Hale G, Waldmann H . Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases Bone Marrow Transplant 1994 13: 597 611","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1126\/science.785599","volume":"193","author":"S Slavin","year":"1976","unstructured":"Slavin S, Strober S, Fuks Z, Kaplan HS . Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation Science 1976 193: 1252 1254","journal-title":"Science"},{"key":"BF1703733_CR8","first-page":"3053","volume":"21","author":"S Slavin","year":"1989","unstructured":"Slavin S, Naparstek E, Aker M et al. The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders Transplant Proc 1989 21: 3053 3054","journal-title":"Transplant Proc"},{"key":"BF1703733_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0163-7258(91)90057-S","volume":"49","author":"W Plunkett","year":"1991","unstructured":"Plunkett W, Saunders PP . Metabolism and action of purine nucleoside analogs Pharmacol Ther 1991 49: 239 268","journal-title":"Pharmacol Ther"},{"key":"BF1703733_CR10","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1016\/S0140-6736(05)64563-1","volume":"348","author":"L Williamson","year":"1996","unstructured":"Williamson L, Wimperis J, Wood M, Woodcock B . Fludarabine treatment and transfusion-associated graft-versus-host disease Lancet 1996 348: 4723","journal-title":"Lancet"},{"key":"BF1703733_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/146532401753174098","volume":"3","author":"G Hale","year":"2001","unstructured":"Hale G . The CD52 antigen and development of the CAMPATH antibodies Cytotherapy 2001 3: 137 144","journal-title":"Cytotherapy"},{"key":"BF1703733_CR12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","volume":"82","author":"MH Gilleece","year":"1993","unstructured":"Gilleece MH, Dexter TM . Effect of Campath-1H antibody on human hematopoietic progenitors in vitro Blood 1993 82: 807 812","journal-title":"Blood"},{"key":"BF1703733_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/332323a0","volume":"332","author":"L Riechmann","year":"1988","unstructured":"Riechmann L, Clark M, Waldmann H, Winter G . Reshaping human antibodies for therapy Nature 1988 332: 323 327","journal-title":"Nature"},{"key":"BF1703733_CR14","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Vinay J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood 2002 99: 3554 3561","journal-title":"Blood"},{"key":"BF1703733_CR15","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukaemia treated with CAMPATH-1H Blood 2001 98: 1721 1726","journal-title":"Blood"},{"key":"BF1703733_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood 2002 100: 768 773","journal-title":"Blood"},{"key":"BF1703733_CR17","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","volume":"99","author":"B Kennedy","year":"2002","unstructured":"Kennedy B, Rawstron A, Carter C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia Blood 2002 99: 2245 2247","journal-title":"Blood"},{"key":"BF1703733_CR18","first-page":"365A","volume":"98","author":"S Faderl","year":"2001","unstructured":"Faderl S, Thomas DA, O'Brien S et al. An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and Rituximab in the treatment of CD52 and CD20-positive chronic lymphocytic disorders Blood 2001 98: 365A","journal-title":"Blood"},{"key":"BF1703733_CR19","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","volume":"16","author":"J Lundin","year":"1998","unstructured":"Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas. A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lympoma J Clin Oncol 1998 16: 3257 3263","journal-title":"J Clin Oncol"},{"key":"BF1703733_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/scd.1.1997.6.351","volume":"6","author":"SM Neudorf","year":"1997","unstructured":"Neudorf SM, Rybka W, Ball E et al. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow J Hematother 1997 6: 351 359","journal-title":"J Hematother"},{"key":"BF1703733_CR21","first-page":"S66","volume":"21","author":"JJ Cornelissen","year":"1998","unstructured":"Cornelissen JJ, Fibbe WE, Schattenberg AV et al. A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation Bone Marrow Transplant 1998 21: (Suppl. 3) S66 S70","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF02798902","volume":"13","author":"L Weiss","year":"1986","unstructured":"Weiss L, Margel S, Slavin S . Depletion of human lymphocytes from peripheral blood and bone marrow by affinity ligands conjugated to agarose-polyacrolein microsphere beads Appl Biochem Biotechnol 1986 13: 87 96","journal-title":"Appl Biochem Biotechnol"},{"key":"BF1703733_CR23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/00007890-198906000-00013","volume":"47","author":"JN Frame","year":"1989","unstructured":"Frame JN, Collins NH, Cartagena T et al. T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads Transplantation 1989 47: 984 988","journal-title":"Transplantation"},{"key":"BF1703733_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0301-472X(99)00056-9","volume":"27","author":"DC Jeong","year":"1999","unstructured":"Jeong DC, Han CW, Jin JY et al. Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility Exp Hematol 1999 27: 1219 1225","journal-title":"Exp Hematol"},{"key":"BF1703733_CR25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/sj.bmt.1700824","volume":"19","author":"A Schattenberg","year":"1997","unstructured":"Schattenberg A, Preijers F, Mensink E et al. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase Bone Marrow Transplant 1997 19: 1205 1212","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1046\/j.1365-2141.1997.d01-3499.x","volume":"98","author":"N Schaap","year":"1997","unstructured":"Schaap N, Schattenberg A, Bar B et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen Br J Haematol 1997 98: 750 759","journal-title":"Br J Haematol"},{"key":"BF1703733_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.bmt.1701476","volume":"22","author":"PV O'Donnell","year":"1998","unstructured":"O'Donnell PV, Jones RJ, Vogelsang GB et al. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies Bone Marrow Transplant 1998 22: 947 955","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/scd.1.1998.7.151","volume":"7","author":"SJ Noga","year":"1998","unstructured":"Noga SJ, Seber A, Davis JM et al. CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment J Hematother 1998 7: 151 157","journal-title":"J Hematother"},{"key":"BF1703733_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/sj.bmt.1700937","volume":"20","author":"E Clarke","year":"1997","unstructured":"Clarke E, Potter MN, Oakhill A et al. A laboratory comparison of T cell depletion by CD34+ cell immunoaffinity selection and in vitro Campath-1M treatment: clinical implications for bone marrow transplantation and donor leukocyte therapy Bone Marrow Transplant 1997 20: 599 605","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/sj.leu.2401781","volume":"14","author":"MA Dao","year":"2000","unstructured":"Dao MA, Nolta JA . CD34: To select or not to select? That is the question Leukemia 2000 14: 773 776","journal-title":"Leukemia"},{"key":"BF1703733_CR31","first-page":"353","volume":"26","author":"ED Zanjani","year":"1998","unstructured":"Zanjani ED, Almeida-Porada G, Livingston AG et al. Human bone marrow CD34\u2212 cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells Exp Hematol 1998 26: 353 360","journal-title":"Exp Hematol"},{"key":"BF1703733_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1749-6632.1999.tb08467.x","volume":"872","author":"ED Zanjani","year":"1999","unstructured":"Zanjani ED, Almeida-Porada G, Livingston AG et al. Engraftment and multilineage expression of human bone marrow CD34\u2212 cells in vivo Ann NY Acad Sci 1999 872: 220 222","journal-title":"Ann NY Acad Sci"},{"key":"BF1703733_CR33","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood.V92.12.4581","volume":"92","author":"G Hale","year":"1998","unstructured":"Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection Blood 1998 92: 4581 4590","journal-title":"Blood"},{"key":"BF1703733_CR34","first-page":"763","volume":"13","author":"P Jacobs","year":"1994","unstructured":"Jacobs P, Wood L, Fullard L et al. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease Bone Marrow Transplant 1994 13: 763 769","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/sj.bmt.1702477","volume":"26","author":"G Hale","year":"2000","unstructured":"Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells Bone Marrow Transplant 2000 26: 69 76","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/146532401317070899","volume":"3","author":"P Rebello","year":"2001","unstructured":"Rebello P, Cwynarski K, Varughese M et al. Phamacokinetics of Campath-1H in bone marrow transplant patients Cytotherapy 2001 3: 261 267","journal-title":"Cytotherapy"},{"key":"BF1703733_CR37","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","volume":"96","author":"PD Kottaridis","year":"2000","unstructured":"Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 2000 96: 2419 2425","journal-title":"Blood"},{"key":"BF1703733_CR38","first-page":"2208","volume":"94","author":"RE Curtis","year":"1999","unstructured":"Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study Blood 1999 94: 2208 2216","journal-title":"Blood"},{"key":"BF1703733_CR39","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood.V91.8.3079.3079_3079_3083","volume":"91","author":"G Hale","year":"1998","unstructured":"Hale G, Waldmann H . Risks of developing Epstein\u2013Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH users Blood 1998 91: 3079 3083","journal-title":"Blood"},{"key":"BF1703733_CR40","first-page":"387","volume":"15","author":"B Hertenstein","year":"1995","unstructured":"Hertenstein B, Hampl W, Bunjes D et al. In vivo\/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT Bone Marrow Transplant 1995 15: 387 393","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR41","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","volume":"99","author":"S Chakrabarti","year":"2002","unstructured":"Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of CAMPATH-1H in delaying immune reconstitution but limiting transplant-related mortality Blood 2002 99: 4357 4363","journal-title":"Blood"},{"key":"BF1703733_CR42","first-page":"203a","volume":"98","author":"SP D'Sa","year":"2001","unstructured":"D'Sa SP, Peggs KS, Thuraisundaram D et al. CAMPATH-1H-containing nonmyeloablative allogeneic stem cell transplantation for myeloma results in delayed T cell reconstitution and a high incidence of viral infections, but low infection-related mortality Blood 2001 98: 203a (Abstr. 847)","journal-title":"Blood"},{"key":"BF1703733_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/sj.bmt.1702108","volume":"25","author":"M Potter","year":"2000","unstructured":"Potter M, Grace S, Ethell M et al. High rate of CMV reactivation (but not disease) in recipient of allogeneic transplants conditioned with CAMPATH-1H Bone Marrow Transplant 2000 25: (Suppl. 1) 135","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR44","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1097\/00007890-200110270-00024","volume":"72","author":"S Chakrabarti","year":"2001","unstructured":"Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity Transplantation 2001 72: 1460 1463","journal-title":"Transplantation"},{"key":"BF1703733_CR45","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1097\/00007890-200004150-00022","volume":"69","author":"GM Davison","year":"2000","unstructured":"Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells Transplantation 2000 69: 1341 1347","journal-title":"Transplantation"},{"key":"BF1703733_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-065X.1998.tb01226.x","volume":"165","author":"K Akashi","year":"1998","unstructured":"Akashi K, Kondo M, Weissman IL . Role of interleukin-7 in T-cell development from hematopoietic stem cells Immunol Rev 1998 165: 13 28","journal-title":"Immunol Rev"},{"key":"BF1703733_CR47","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1182\/blood.V97.6.1525","volume":"97","author":"TJ Fry","year":"2001","unstructured":"Fry TJ, Christensen BL, Komschlies KL et al. Interleukin-7 restores immunity in athymic T-cell-depleted hosts Blood 2001 97: 1525 1533","journal-title":"Blood"},{"key":"BF1703733_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.bmt.1701540","volume":"23","author":"A Grigg","year":"1999","unstructured":"Grigg A, Bardy P, Byron K et al. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma Bone Marrow Transplant 1999 23: 107 110","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR49","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","volume":"89","author":"S Giralt","year":"1997","unstructured":"Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531 4536","journal-title":"Blood"},{"key":"BF1703733_CR50","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756 763","journal-title":"Blood"},{"key":"BF1703733_CR51","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817 2824","journal-title":"J Clin Oncol"},{"key":"BF1703733_CR52","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0889-8588(05)70108-8","volume":"13","author":"R Champlin","year":"1999","unstructured":"Champlin R, Khouri I, Kornblau S et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy Hematol Oncol Clin North Am 1999 13: 1041 1058","journal-title":"Hematol Oncol Clin North Am"},{"key":"BF1703733_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.bmt.1702204","volume":"25","author":"AM Carella","year":"2000","unstructured":"Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans (editorial) Bone Marrow Transplant 2000 25: 345 350","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR54","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/sj.bmt.1702392","volume":"25","author":"A Nagler","year":"2000","unstructured":"Nagler A, Slavin S ., Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma Bone Marrow Transplant 2000 25: 1021 1028","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR55","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1046\/j.1365-2141.2000.01879.x","volume":"108","author":"GM Cull","year":"2000","unstructured":"Cull GM, Haynes AP, Byrne JL et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity Br J Haematol 2000 108: 754 760","journal-title":"Br J Haematol"},{"key":"BF1703733_CR56","first-page":"60","volume":"25","author":"IW Flinn","year":"1998","unstructured":"Flinn IW, Vogelsang G . Bone marrow transplantation for chronic lymphocytic leukemia Semin Oncol 1998 25: 60 64","journal-title":"Semin Oncol"},{"key":"BF1703733_CR57","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/bjc.1998.381","volume":"77","author":"P Dreger","year":"1998","unstructured":"Dreger P, von Neuhoff N, Kuse R et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer 1998 77: 2291 2297","journal-title":"Br J Cancer"},{"key":"BF1703733_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.bmt.1701869","volume":"24","author":"P Jindra","year":"1999","unstructured":"Jindra P, Koza V, Fiser J et al. Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications Bone Marrow Transplant 1999 24: 215 217","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR59","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/sj.bmt.1700730","volume":"19","author":"M Itala","year":"1997","unstructured":"Itala M, Pelliniemi TT, Rajamaki A, Remes K . Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield Bone Marrow Transplant 1997 19: 647 651","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR60","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/sj.bmt.1701503","volume":"22","author":"R Scime","year":"1998","unstructured":"Scime R, Indovina A, Santoro A et al. PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia Bone Marrow Transplant 1998 22: 1159 1165","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR61","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.bmt.1702026","volume":"24","author":"S Schey","year":"1999","unstructured":"Schey S, Ahsan G, Jones R . Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study Bone Marrow Transplant 1999 24: 989 993","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR62","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1046\/j.1365-2141.1997.1062924.x","volume":"97","author":"MJ Dyer","year":"1997","unstructured":"Dyer MJ, Kelsey SM, Mackay HJ et al. In vivo \u2018purging\u2019 of residual disease in CLL with Campath-1H Br J Haematol 1997 97: 669 672","journal-title":"Br J Haematol"},{"key":"BF1703733_CR63","first-page":"603a","volume":"94","author":"S Kennedy","year":"1999","unstructured":"Kennedy S, Rawstron A, Evans P et al. Campath-1H therapy in 29 patients with refractory CLL: \u2018true\u2019 complete remission is an attainable goal Blood 1999 94: (Suppl. 1) 603a (Abstr. 2683)","journal-title":"Blood"},{"key":"BF1703733_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","volume":"124","author":"M Michallet","year":"1996","unstructured":"Michallet M, Archimbaud E, Bandini G et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry Ann Intern Med 1996 124: 311 315","journal-title":"Ann Intern Med"},{"key":"BF1703733_CR65","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO.1994.12.4.748","volume":"12","author":"IF Khouri","year":"1994","unstructured":"Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results J Clin Oncol 1994 12: 748 758","journal-title":"J Clin Oncol"},{"key":"BF1703733_CR66","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/sj.bmt.1702237","volume":"25","author":"ZS Pavletic","year":"2000","unstructured":"Pavletic ZS, Arrowsmith ER, Bierman PJ et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia Bone Marrow Transplant 2000 25: 717 722","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR67","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228","volume":"88","author":"D Provan","year":"1996","unstructured":"Provan D, Bartlett-Pandite L, Zwicky C et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation Blood 1996 88: 2228 2235","journal-title":"Blood"},{"key":"BF1703733_CR68","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/146532401753174034","volume":"3","author":"RJ Lush","year":"2001","unstructured":"Lush RJ, Haynes AP, Byrne JL et al. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPAH (+\/\u2212fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion Cytotherapy 2001 3: 203 210","journal-title":"Cytotherapy"},{"key":"BF1703733_CR69","first-page":"184a","volume":"98","author":"G Carrum","year":"2001","unstructured":"Carrum G, Przepiorka D, Popat U et al. Submyeloablative conditioning regimens using anti-lymphocyte antibodies for allogeneic stem cell transplantation Blood 2001 98: 184a (Abstr. 775)","journal-title":"Blood"},{"key":"BF1703733_CR70","doi-asserted-by":"publisher","first-page":"420a","DOI":"10.1182\/blood.V98.12.3486","volume":"98","author":"DA Rizzieri","year":"2001","unstructured":"Rizzieri DA, Long GD, Vredenburgh JJ et al. Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells Blood 2001 98: 420a (Abstr. 1764)","journal-title":"Blood"},{"key":"BF1703733_CR71","doi-asserted-by":"publisher","first-page":"669a","DOI":"10.1182\/blood.V98.12.3486","volume":"98","author":"DA Rizzieri","year":"2001","unstructured":"Rizzieri DA, Long GD, Vredenburgh JJ et al. Non-myeloablative transplantation using CAMPATH 1H for T depletion of mismatched, related donor peripheral blood stem cells Blood 2001 98: 669a (Abstr. 2805)","journal-title":"Blood"},{"key":"BF1703733_CR72","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V82.4.1366.1366","volume":"82","author":"SN Rabinowe","year":"1993","unstructured":"Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia Blood 1993 82: 1366 1376","journal-title":"Blood"},{"key":"BF1703733_CR73","first-page":"251","volume":"7","author":"G Bandini","year":"1991","unstructured":"Bandini G, Michallet M, Rosti G, Tura S . Bone marrow transplantation for chronic lymphocytic leukemia Bone Marrow Transplant 1991 7: 251 253","journal-title":"Bone Marrow Transplant"},{"key":"BF1703733_CR74","first-page":"748","volume":"12","author":"CL Toze","year":"1994","unstructured":"Toze CL, Shepherd JD, Connors JM et al. Allograftingfor indolent lymphoid neoplasms Ann Oncol 1994 12: 748 758","journal-title":"Ann Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703733","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703733.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703733.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:24:24Z","timestamp":1648077864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,1]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12,1]]}},"alternative-id":["BF1703733"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703733","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12,1]]},"assertion":[{"value":"12 December 2002","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}